Astrocytes are glial cells specific to the central nervous system and involved in numerous brain functions, including regulation of synaptic transmission and of immune reactions. There is mounting evidence suggesting astrocytic dysfunction in psychopathologies such as major depression, however, little is known about the underlying etiological mechanisms. Here we report a two-stage study investigating genome-wide DNA methylation associated with astrocytic markers in depressive psychopathology. We first characterized prefrontal cortex samples from 121 individuals (76 who died during a depressive episode and 45 healthy controls) for the astrocytic markers GFAP, ALDH1L1, SOX9, GLUL, SCL1A3, GJA1 and GJB6. A subset of 22 cases with consistently downregulated astrocytic markers was then compared with 17 matched controls using methylation binding domain-2 (MBD2) sequencing followed by validation with high-resolution melting and bisulfite Sanger sequencing. With these data, we generated a genome-wide methylation map unique to altered astrocyte-associated depressive psychopathology. The map revealed differentially methylated regions (DMRs) between cases and controls, the majority of which displayed reduced methylation levels in cases. Among intragenic DMRs, those found in GRIK2 (glutamate receptor, ionotropic kainate 2) and BEGAIN (brain-enriched guanylate kinase-associated protein) were most significant and also showed significant correlations with gene expression. Cell-sorted fractions were investigated and demonstrated an important non-neuronal contribution of methylation status in BEGAIN. Functional cell assays revealed promoter and enhancer-like properties in this region that were markedly decreased by methylation. Furthermore, a large number of our DMRs overlapped known Encyclopedia of DNA elements (ENCODE)-identified regulatory elements. Taken together, our data indicate significant differences in the methylation patterns specific to astrocytic dysfunction associated with depressive psychopathology, providing a potential framework for better understanding this disease phenotype.
INTRODUCTION
Glial cells account for at least 75% of brain cells 1 and are implicated in a range of psychiatric disorders, including alcoholism, 2 schizophrenia, 3 depression 4 and suicide. 5, 6 In particular, astrocytic dysfunction is evident in depressive psychopathologies including suicide. 4 Astrocytes are multifaceted cells with numerous functions, including regulation of blood flow, synaptic communication and plasticity, immune regulation 7 and maintenance of neuronal functioning. 8 These-and other-physiological roles are likely to have an impact in depression and suicide, given evidence from postmortem and animal studies showing altered astrocytic morphologies 5 and persistently decreased expression of astrocyte-specific genes such as glial fibrillary acidic protein (GFAP), 9 glutamine synthetase (GLUL), 10 the glial high-affinity transporters, SLC1A2 and SLC1A3, 10 aquaporin 4 (ref. 11 ) and the connexin genes such as Cx30 and Cx43. 6 Despite consistent reports, little is known about the underlying etiological mechanisms linking astrocytic dysfunction to depression and suicide. These could involve epigenetic factors such as DNA methylation that stably modulates gene expression. Indeed, DNA methylation changes at specific genomic loci are associated with increased risk of psychopathology. 12, 13 The purpose of the current study was to identify DNA methylation patterns associated with astrocytic alterations in depression and suicide.
To this end, we characterized expression of astrocytic markers GFAP, ALDH1L1, SLC1A3, GJA1, GJB6, GLUL and SOX9 in the dorsolateral prefrontal cortex (PFC) of individuals having died by suicide and sudden death controls. For all subjects with consistent and pronounced downregulation of astrocytic markers, we conducted methylation binding domain-2 (MBD2) enrichment coupled with next-generation sequencing. Our results suggest a framework to better understand how astrocyte dysfunction impacts depression and suicide.
MATERIALS AND METHODS

Brain samples, clinical characterization and group composition
Brain tissue was obtained from the Douglas-Bell Canada Brain Bank (DBCBB; http://www.douglas.qc.ca/page/brain-bank). The DBCBB recruits suicide cases and sudden death control subjects. To avoid prolonged agonal states, both cases and controls recruited to the bank cannot undergo resuscitation procedures or medical intervention. Brain tissue for the DBCBB is collected after consent is obtained from next-of-kin. Families are recontacted after~4 months to undergo a series of structured interviews, known as psychological autopsies, with the person best acquainted with the deceased, as described elsewhere.
14 Interviews are supplemented with information from archival material obtained from hospitals, the Coroner's office or social services. Following the interviews, clinical vignettes are produced and assessed by a panel of clinicians to generate Diagnostic and Statistical Manual of Mental Disorders-IV diagnoses. This is a well-accepted and valid procedure to obtain clinical information on deceased individuals through proxy-based interviews. 15, 16 Cases in this study were individuals who died by suicide as determined by the coroner and following psychological autopsies met the criteria for major depressive disorder or had no axis I, but with evidence of depressive symptoms at the moment of death. Controls were individuals who died suddenly in motor vehicle accidents or by cardiac arrest and did not have evidence of axis I disorders. For preliminary screening, we included 121 brain samples (76 cases) and tested two cortical brain regions. Low expressors were identified using tissue from Brodmann area 10 and then replicated in tissue from Brodmann area 8/9. Only tissue from the left hemisphere (gray matter only) was used. These cortical regions are consistently implicated in depression [17] [18] [19] [20] and are involved in higher order functioning such as decision making, which is impaired in suicide. 21 The second part of this study used expression profiles to define the case group. Specifically, at least 5/7 genes investigated had to be in the lowest quartile (n = 22) of expression ( Supplementary Figure 1-3 ). Controls were selected on the basis of age, gender and post mortem interval to groupmatch the suicide group; gene expression was not used to select controls. The average post mortem interval (± s.e.m.) for controls was 18.8 ( ±2.91) and for cases was 17.7 (±4.48). The average age of controls was 41.3 (±5.87) and for suicides was 41.0 (±2.64); and the average RNA integrity number for controls was 6.2 (±0.16) and for suicides was 6.4 (±0.16). There was no significant difference between groups for any of these variables. This study was approved by the Douglas Institute Research Ethics Board.
Methods for histological sectioning, gene expression analysis, MBD protein sequencing (MBD2-seq), sequencing analysis, Encyclopedia of DNA elements (ENCODE) analysis, high-resolution melting and site-specific bisulfite sequencing, fluorescence activated cell sorting (FACS) and functional cell assays can be found in the online Supplementary Information (Supplementary Methods).
RESULTS
Identification of cases with low expression of astrocyte-related genes To identify subjects with potential astrocytic dysfunction, we screened PFC samples obtained from the DBCBB for expression levels of genes exclusively or primarily expressed in astrocytes. This initial screen was conducted on 121 subjects (87 males), including 76 individuals who died by suicide, and 45 sudden death controls. We selected the following seven genes for screening based on their high expression in astrocytes: GFAP, ALDH1L1, SOX9, GLUL, SCL1A3, GJA1 and GJB6, all showing significantly decreased expression in cases compared with controls ( Figure 1 ). To demonstrate that these results specifically reflected a decrease in astrocyte gene expression, we examined the level of NeuN (a.k.a. RBFOX3), a well-known marker of neurons 22 and found no significant difference between cases and controls ( Figure 1h) .
Epigenetic factors are known to regulate gene expression and may contribute to the astrocytic dysfunction observed in our cases. Specifically, we hypothesized that DNA methylation patterns differ between groups. To test this, we conducted a genome-wide methylation sequencing study focusing on individuals with the most severe molecular phenotype. We selected cases showing the lowest mRNA expression levels of the astrocyte marker genes used for screening, and operationally defined extreme cases by expression levels in the bottom quartile for at least 5/7 genes; 22 cases met these criteria (Supplementary Figure  1-5; and Supplementary Tables 1 and 2 ). Cases were compared with 17 psychiatrically normal controls grouped-matched according to age, RNA integrity number, post mortem interval and gender. To decrease variability, all subjects included in the analysis were males.
Generation of high-quality genome-wide MBD2-seq profiles We performed genome-wide DNA methylation analysis by isolating fragmented DNA using biotinylated-MBD2. The MBD2 protein specifically targets densely methylated CpGs 23 and does not target hydroxymethylated cytosines, 23, 24 thus sequencing MBD2-enriched DNA identifies methylated regions from the whole genome. Comparing the number of sequenced reads matching each region enabled us to identify methylation differences between cases and controls. Many quality control steps where preformed to insure high quality ( Supplementary Figures 6 and 7 ; and Supplementary Table 3 ). Figure 1 . Quantitative PCR screening of 76 cases and 45 controls for astrocytic genes showed a strong decrease in expression of astrocyte markers in Brodmann area 10. (a) GFAP; (mean ± s.e.m.), case (1.17 ± 0.13), control (2.27 ± 0.40), P = 0.0068; (b) ALDH1L1, case (1.12 ± 0.13), control (2.08 ± 0.31), P = 0.0023; (c) SOX9, case (1.48 ± 0.22), control (2.41 ± 0.64), P = 0.03; (d) GLUL, case (1.02 ± 0.12), control (1.46 ± 0.21), P = 0.01; (e) SCL1A3, case (1.63 ± 0.28), control (2.12 ± 0.52), P = 0.04; (f) GJA1, case (1.17 ± 0.14), P = 0.03; (g) GJB6, case (1.48 ± 0.23), control (2.41 ± 0.64), P = 0.05; (h) expression of RBFOX3 (a.k.a. NeuN, a standard marker for mature neuronal identity) shows no difference between groups (P = 0.86). (Tests performed were either Student's t-test or Mann-Whitney U-test, depending on the distribution of the data). *Pr0.05; **P r 0.001.
In total, we obtained nearly 450 million reads, and mean read counts were similar between groups (Student's t-test, P = 0.85) (Supplementary Table 4 ). Our reads provided 20x coverage per base for the MBD enrichment (Supplementary Figure 8) . We assessed our data for genomic metrics, irrespective of disease status. First, we assessed the consistency of sequencing data by measuring overall methylation levels at specific genomic features. DNA methylation levels were consistent with expectations at all genomic loci assessed: CpG islands showed the least amount of methylation, first exons showed less methylation than other exons and imprinted regions showed increased levels of methylation ( Figure 2a ; Wilcoxin rank-sum, P o 2E10-22).
Second, to validate the enrichment of methylated reads and to confirm bioinformatic processing, we selected regions of the genome identified in sequencing data as either highly methylated or poorly methylated and re-performed MBD2 enrichment reactions using identical DNA samples as the initial sequencing reaction. We found that levels identified as highly methylated in the sequencing reaction gave the lowest Ct values in quantitative real time-PCR analysis, and the opposite was found in genomic regions with low methylation (region 1: r = − 0.81, t = 0.025; region 2 r = − 0.74, t = 0.047; and region 3: r = − 0.61, t = 0.09) (Supplementary Figure 9) . Differentially methylated regions in cases and controls After ensuring quality and accuracy of MBD2 enrichment, we assessed case and control group differences. There were 115 differentially methylated regions (DMRs) across the genome. Of these, 33.91% (N = 34) were found in genes, almost all intragenic and falling within introns (N = 31; 31.3%). Nearly 11% (N = 14) of DMRs were within promoters, defined as sequences up to 5 kb upstream of transcription start sites (Figure 2b ). However, the majority of DMRs were found in intergenic regions 56.6% (N = 66).
As expected, the number of reads mapping back to each chromosome strongly correlated with their size (Spearman r = 0.83, P o0.0001), while there was no difference in the contribution of each group to chromosome coverage ( Supplementary  Figures 10a and b) . We found no relationship between chromosome size and location of DMR, that is, DMRs were independent of size and read count (Spearman r = − 0.15, P = 0.48) (Supplementary Figure 10c) .
Most DMRs were hypomethylated in cases. There was considerable decrease in methylation within the gene body of cases; 58.8% of the within gene DMRs were less methylated in cases compared with controls, and these results were consistent in the intergenic regions, where a similar percentage of DMRs were hypomethylated (57.6%; Figure 2c ).
We observed two genomic regions enriched with DMRs clusters: one on chromosome 10 and another on the X chromosome (Fisher's exact test, FDRo 0.05; Supplementary Table 5 ; and Supplementary Figure 11 ). The DMRs in these two regions overlapped strongly with ENCODE elements suggesting potentially important regulatory roles. 25 Functional relevance of DMRs derived from ENCODE data Using publically available data from the ENCODE, we performed an in silico assessment of the regulatory potential of each DMR by identifying overlaps with ENCODE features. Altogether, we assessed 41 ENCODE features that include histone modifications and DNA-binding proteins known to influence gene transcription. Our analysis showed enrichment for 37 of the 41 features in hypomethylated regions (Fisher's exact test average Po4.82E-03; Supplementary Table 6); however, there was no enrichment in hypermethylated sites. Nearly half the DMRs contained at least one ENCODE feature (Figure 3a) . Histone 3 lysine 4 trimethylation (H3K4me3), a chromatin modification enriched in gene promoters and most often associated with euchromatin and active transcription, 26 and DNase I hypersensitivity sites (DHSs) that are associated with many cis-regulatory elements including promoters, enhancers, insulators, silencers and locus control regions, 27 overlapped most frequently with the DMRs (Figure 3b ). Both features overlapped with 22.6% of DMRs. As DHSs have been shown to precede promoter regions marked by H3K4me3, 27 it was not surprising that most DHS sites overlapped with H3K4me3. We found four DMRs with an impressive overlap of 20 or more ENCODE features. These regions were found in the pericentromeric region of four different chromosomes (4, 7, 16 and 21) . One of the most conserved functions of DNA methylation is stabilizing pericentromeric repeats by inhibiting their latent transcriptional potential. 28 Moreover, decondensing of these heterochromatic regions can result in illegitimate rearrangements, 29 therefore hypomethylation in these regions often lead to notable consequences.
To assess the permissive or inhibitory relationship of the ENCODE data with our data, we grouped the ENCODE features into active or repressive marks based on their known function (Supplementary Tables 6-8 ). The distribution of DMRs falling into each category was comparable, with 45% overlapping repressive elements and 55% overlapping active elements (Figure 3c ).
Differentially methylated astrocytic genes As our subjects were selected based on astrocytic expression patterns, we were interested in potential associations between DMRs and astrocyte and/or astrocyte-regulatory genes. To assess whether these genes were associated with DMRs, we conducted gene ontology analyses focusing on genes highly expressed in astrocytes and genes coding for regulatory factors of astrocytic expression. There were four astrocyte-associated genes coded within regions of differential methylation ( Gene-specific validation of DMRs showed inverse correlation to gene expression levels We validated the most significant DMRs, focusing on the DMRs related to astrocytic function (Table 1 ) and the complete intragenic DMRs (Supplementary Table 10 ). These DMRs were, respectively, in GRIK2 (glutamate receptor, ionotropic kainate 2) and BEGAIN (brain-enriched guanylate kinase-associated protein; Figures 4a and b) . GRIK2 is implicated in astrocytic function and has been associated with mood disorders, [30] [31] [32] [33] whereas BEGAIN is associated with cellular communication. 34 For validation, we performed both bisulfite cloning (Bs-Cloning) and highresolution melting (HRM) analysis. In both cases, DMRs were consistent with the MBD2-seq analysis, though as expected, HRM showed less sensitivity. HRM results are presented in Figures 4c and g, and show significant differences for both GRIK2 (Student's t-test, P = 0.02) and BEGAIN (Student's t-test, P = 0.007) in the same direction observed with the MBD2-seq data. With Bs-cloning, we achieved base-pair resolution of methylation levels for GRIK2 and BEGAIN, which strongly supported the MBD2-seq data. (Figures 4d  and h; and Supplementary Tables 9a and b) . Next, we measured expression levels for each gene, finding an increase in GRIK2 expression in cases (Figure 4e ; P = 0.012). For BEGAIN, there are two major transcripts with little known about their expression patterns. We investigated brain and peripheral tissues, and found that variant 1 has increased expression in the brain (Figure 4j ). When we assessed expression of BEGAIN transcripts, we observed a marked decrease of variant 1 in cases (2.3-fold decrease, Po0.0001), whereas variant 2 remained unchanged (Figures 4k and l) . Analysis of cluster CpGs methylation and expression showed a significant inverse correlation for both GRIK2 (Figure 4f , r = − 0.37, Po0.05) and BEGAIN (Figure 4m , r = − 0.37, Po0.05), suggesting a role for methylation regulating expression in these genes.
Non-neuronal cells from case samples drive methylation difference in BEGAIN As DNA methylation is known to be cell-type specific, we used FACS to separate tissue homogenates into neuronal and nonneuronal fractions. Although it is currently methodologically challenging to isolate astrocytic fractions from frozen tissue, the non-neuronal fraction is primarily composed of astrocytes as they make up the bulk of non-neuronal cells of the human brain. We collected nuclei marked with NeuN and unmarked nuclei for all samples. DNA from each fraction was directly bisulfite converted, then subjected to cloning and Sanger sequencing as for validation of brain homogenates. For GRIK2, we observed no difference in methylation across cell types (Supplementary Figure 14d) , however, for BEGAIN we observed a marked increase of methylation for cases in the non-neuronal fraction, suggesting that the sizeable difference in methylation between cases and controls was largely driven by non-neuronal cells (Figure 4i ; one-way analysis of variance (ANOVA); F(3,32) = 10.74, P o0.0001).
DNA methylation in DMR represses transcription
Considering the strong increase of methylation detected in both the homogenate and non-neuronal cellular fraction of BEGAIN, we decided to assess this region in a functional cell assay to determine the direct consequences of methylation. As suggested by the CHROMHMM from ENCODE (Supplementary Figure 15) , this region of BEGAIN has both promoter and enhancer capabilities, therefore the 474-bp amplicon was inserted into two separate CpG-free vectors, one containing no endogenous promoter (Figure 5a ) to test potential promoter activity and a second under the control of the human EF-1α promoter to test enhancer-like activity (Figure 5b ). The inserted amplicons were either fully methylated or fully unmethylated, the report assays were performed in quintuplicate and repeated twice independently. This 474-bp region of BEGAIN clearly showed promoter activity that was fully repressed by methylation (Figure 5c ; Kruskal-Wallis = 19.94, d.f., 3, P o0.0001; Supplementary Figures  15a and b) . Equally, when this region of BEGAIN was inserted in an enhancer position next to the human EF-1α promoter, methylation caused complete loss of reporter gene expression (Figure 5d ; Kruskal-Wallis = 22.15, d.f., 3, P o0.0001; Supplementary Figures  15c and d) . These results indicate a potent effect of DNA methylation on this region of BEGAIN and suggest a potentially causative role of methylation in the downregulation of the BEGAIN variant 1 that we observed in cases with astrocytic dysfunction.
DISCUSSION
In this study, we investigated genomic DNA methylation patterns that may contribute to astrocyte dysfunction in depression and suicide. First, we characterized groups for their expression profile of several astrocyte-associated genes in the PFC. Subsequently, we conducted MBD2-seq focusing on cases with clear astrocytic dysfunction at a molecular level. The profiles generated in our study revealed differential DNA methylation at multiple loci, including ENCODE-associated regulatory sequences. In followingup our top intragenic DMRs, we were able to replicate our findings Abbreviations: Adj, adjusted; Avg, average; ENCODE, Encyclopedia of DNA elements; TES, transcription end site. These genes were selected based on functions such as cation homeostasis, response to oxidative stress and glutamatergic synaptic transmission. Genes were supplemented by the addition of genes described by Cahoy et al. 30 as enriched in astrocytes. Some genes have multiple windows of methylation differences; altogether, this list represents seven DMRs of the previously described 34 gene-based DMRs (~21%). 'Meth status' refers to whether the regions show an increase (↑) or decrease (↓) in methylation. 'ENCODE overlap' refers to either DHS or H3K4me3, both or no overlap with the DMR. 'Region' describes the general genomic region where the DMR is found for that gene. 'Strand' refers to the location of the genes, either on the sense (+) or antisense ( − ) strand. 'Avg log 2 fold change' is the absolute difference of methylation at that site, it is averaged to account for the multiple windows (DMRs) found in the gene. 'Avg adj P-value' is the significance of the fold change adjusted to correct for multiple testing, averaged as before. 'No. of win' is the number of windows found within that gene; a window represents a DMR. 'Function' is a brief functional description of the gene. The list is ranked by DMR containing windows, and then lowest Avg adj P-value and Avg log 2 fold change. a This DMR is technically not in the primary variant of ROPN18.
Astrocytic abnormalities and DNA methylation patterns C Nagy et al using two independent techniques, and in addition, we found that the methylation differences correlated with gene expression changes. Furthermore, we demonstrated that in cases, nonneuronal cells drive methylation changes observed in BEGAIN. Finally, we showed through functional cell assays that methylation of our isolated region in BEGAIN almost completely abolishes reporter gene expression in vitro. This is, to our knowledge, the first study using next-generation sequencing to investigate genome-wide differential methylation associated with depression and suicide.
Most DNA methylation studies use candidate approaches; among the strengths of the current study is the genome-wide approach coupled by DNA sequencing. Studies in rats and humans have shown discrete regions of hypermethylation associated with behavioral phenotypes and transcriptional regulation. 35, 36 These studies used candidate gene approaches or were focused on promoter sequences. 37 In the present study, we avoided restricting our analyses to promoter regions, and provided an unbiased view of DNA methylation associated with depressive psychopathology and suicide. About 90% of the DMRs Figure 4 . Gene-specific validation of differentially methylated regions (DMRs) shows inverse correlation to gene expression levels, and fluorescence activated cell sorting (FACS) shows specific non-neuronal contribution. Schematic diagrams of each gene highlighting region of methylation difference, the size of amplicon and the number and distribution of CpGs for each (a) GRIK2 and (b) BEGAIN, respectively. (c) Highresolution melting (HRM) results for GRIK2 that show a decreased methylation in cases (unpaired t-test, *P = 0.025). (d) Bs-cloning supports MBD-seq and HRM results showing a cluster of the first nine CpGs as significantly less methylated in cases (n = 21, average 17 clones per sample) than controls (n = 20, average 17 clones per sample) mixed model regression analysis was perform to assess significance of methylation at each CpG, *Po0.05, **P o0.01, ***P o0.001 exact values for pairwise comparison are in Supplementary Table 9a and cluster  analysis in Supplementary Table 9b) . (e) GRIK2 expression as measured by relative quantitation using TAQMAN probes shows an increasing in expression in cases (Student's t-test, *P = 0.012). (f) GRIK2 expression correlates with the cluster of significantly differentially methylated CpGs (average methylation at each CpG, Spearman r = − 0.37, *P = 0.012). (g) HRM results for BEGAIN show more methylation in cases compared with controls with (unpaired t-test with Welch's correction, **P = 0.007). (h) Bs-cloning for BEGAIN shows striking increase in methylation of cases (n = 17, average 11 clones per sample) compared with controls (n = 18, average 11 clones per sample) mixed model regression analysis was perform to assess significance of methylation at each CpG; *P o0.05, **P o0.01, # Po0.00, ϕ trend 0.053, exact values for pairwise comparison are in Supplementary Table 9c and cluster analysis in 9d). Cases showed on average a threefold increase in methylation within cluster on BEGAIN. (i) BEGAIN FACS samples show a strong contribution of methylation from the non-neuronal cell fraction in case samples, whereas there is no difference in controls sample methylation between the two fractions (n = 9 for all groups, average 17 clones per sample, one-way ANOVA F(3.32) = 10.74, P o0.0001, Tukey's post hoc, *Po0.05, ***Po 0.001). (j) Analysis of BEGAIN variant expression in brain and blood. Experiment was independently repeated three times with two endogeneous controls per experiment, geometric mean of endogenous control was calculated and expression was normalized to this value. We qualitatively show that variant 1 is more expressed in brain and almost not present in blood, while we still detect variant 2 in blood. (k) The astrocytic dyfunction group show a 2.3-fold decrease in the expression of BEGAIN variant 1 compared with controls (Mann-Whitney U-test; P o0.0001), (l) whereas variant 2 shows no change (Student's t-test, P = 0.26). (m) The decrease in variant 1 expression correlates with the significantly differentially methylated cluster of CpGs in BEGAIN (average methylation at each CpG, Spearman r = − 0.37, *P = 0.019).
were found in non-promoter regions where the relationship with expression is variable. We found many DMRs in gene bodies, where methylation is commonly associated with active transcription. 38 Our results are consistent with a regulatory mechanism for repressing transcription in these regions. For example, a reduction of gene body methylation can result in de novo histone modifications 39 that decrease transcription. As many of the DMRs in this study were found within gene bodies and intergenically, hypomethylation may result in gene repression.
Our study provides valuable information about oftenoverlooked regions of the genome. 40 In support of our findings, most variability in methylation occurs in gene bodies and intergenic regions, rather than promoters and upstream regulatory regions. 41 We identified two cluster regions, on chromosome 10 and the X chromosome, where DMRs fell primarily on shortand long-interspersed elements. DNA methylation maintains the stability of the genome by silencing these mobile elements. 42 Decreased methylation and increased expression of these elements could disrupt gene transcription. In addition, reduced methylation in these clusters could alter associated chromatin. 43 Moreover, four of the DMRs that we found within pericentromeric regions overlapped with over 20 ENCODE elements, representing regions under extensive epigenetic control. Abnormal methylation in these regions is implicated in developmental disorders, 44 suggesting important functional consequences. 45 Among intragenic DMRs, we selected two according to significance for additional work: GRIK2 and BEGAIN. GRIK2 codes for glutamate ionotropic kainate receptor that is a ligand-gated cation channel. This channel is associated with gray and white matter astrocytes, 30 and altered calcium signaling in response to antidepressants.
32 GRIK2 has been previously associated with psychiatric and neurological disorders, [30] [31] [32] 46 including depression. [30] [31] [32] Our combined data showed that GRIK2 is hypomethylated in intron 13 in cases as compared with controls, and we suspect that this intronic region of hypomethylation may influence alternative splicing of GRIK2, 47 potentially favoring the protein isoform with reduced permeability calcium signaling; however, additional work is required to explore this hypothesis.
BEGAIN, on the other hand, showed on average a threefold increase in methylation in cases, representing one of the strongest changes reported to date in psychiatric phenotypes. BEGAIN is poorly studied in humans but has been associated with diabetes and autoimmune disorders, 48 an interesting finding considering the growing evidence for the inflammatory basis of depression 49, 50 and the role of astrocytes in the regulation of neuroinflammation. 51 In addition, a study in rats has shown increased BEGAIN expression in the frontal pole in response to prenatal stress as a paradigm for the etiology of schizophrenia. 52 BEGAIN is highly associated to the postsynaptic density proteins, and particularly to the postsynaptic density 95 (PSD95), 34, 53, 54 having 90% co-localization with PSD95, 53 and a role in sustaining the structure of this scaffolding protein. 55 PSD95 is the protein found in the postsynapic dendritic heads of excitatory synapses, and has been implicated in the coordination of the downstream communication of glutamate receptors, including GRIK2, through the binding of PSD95 to its guanylate kinase domains. 56 Recently, it has been shown that the astrocytes forming part of this excitatory synapse may have an important role in regulating the excitatory/inhibitory balance of neurons through PSD95. 57 The epigenetic alterations to BEGAIN and GRIK2 and their association to astrocytically mediated PSD95 suggest possible defective synaptic communication and/or synaptic plasticity. 54 Interestingly, our two top hits are involved in synaptic communication and regulation. 34, 58 Whereas GRIK2 is known to be expressed in astrocytes and to be directly involved in astrocytemediated responses to antidepressant drugs, 31, 32, 46 BEGAIN has no known association to astrocytes. However, as the primary contribution of methylation was found in non-neuronal cells, it appears that astrocytes have a functional role in the regulation of this gene via methylation alterations. Otherwise, this would not be the first time that changes to genes in astrocytes at an epigenetic level are seen to influence normal neuronal function. For instance, Tao et al. 59 showed that selectively knocking-out Dicer in astrocytes leads to neuronal dysfunction and degeneration. Thus far BEGAIN has been investigated and localized in nuclei and synapses of neurons, 53 but there is no information on its relation to astrocytes. Much like GRIK2, BEGAIN could have an important role in both cell types. As BEGAIN is thought to maintain the structure of the postsynaptic density it would be interesting to see if the strong reduction of its transcript results in altered dendritic morphology as has become one of the emerging theories of autism, schizophrenia and Alzheimer's. 60 This study has opened the door to this and many other questions.
Our study is not without limitations. MBD2 has a higher affinity to densely methylated CpGs than antibody-based approaches; therefore, we may be missing single base-pair differences. Conversely, MBD2 is able to discriminate between 5′ hydroxymethylcytosine and 5′ methylcytosine 24 with greater efficiency than the monoclonal antibody directed against 5-methylcytidine. 61 Regarding our sample selection, altered transcription is often used as a marker for astrocytic dysfunction, 6, 9, 10 however, astrocyte dysfunction can be defined in many ways and may not be reflected by gene expression differences. Finally, we limited this study to DNA methylation changes and thus did not examine other epigenetic mechanism that may be involved in gene regulation. Despite these limitations, our study produced a list of DMRs showing clear evidence of astrocytic dysfunction in individuals who were depressed and died by suicide. Furthermore, we identified two genes involved in synaptic communication, GRIK2 and BEGAIN, which appear to be regulated by DNA methylation in cases with astrocytic dysfunction. Each DMR identified here provides avenues for further investigation of the pathophysiological mechanisms underlying astrocytic dysfunction in mood disorders.
